Press Releases

Cannasat Therapeutics Reports Results for the Nine Months Ended September 30, 2021

MarketWire, November 28, 2021

Operational Highlights

Commenced first Phase I clinical study for CAT 310, a potential treatment for patients with neuropathic pain and other conditions

Continued formulation work on CAT 320, a non-psychoactive, potential treatment for anxiety and other mood disorders


Financial Highlights

Cash and cash equivalents at September 30, 2021 of $1,100,021.

Received $480,000 from Prairie Plant Systems, representing repayment of an outstanding debenture

Net loss of $646,172 for the three months ended September 30, 2021 (2006: $474,452), in line with expectation.

Report 70,010,516 common shares outstanding at September 30, 2007.


In announcing the results, David Hill, Chief Executive Officer of Cannasat, said:

"During the third quarter, Cannasat commenced clinical studies of our lead product, CAT 310. This first study in humans will provide us with our first set of important clinical safety and pharmacokinetic data that will guide formulation development. This is a major milestone for the Company and keeps us on track to move CAT 310 to Phase II testing by the end of 2008."

About Cannasat Therapeutics

Founded in 2004, Cannasat is an early stage pharmaceutical research and development company. Cannasat is developing cannabinoid-based pharmaceutical products using proprietary formulation and drug delivery technologies. Cannabinoids have broad therapeutic applications which are believed to include the treatment of neuropathic pain, chronic pain, depression, anxiety and movement disorders. More information about Cannasat (TSX-V: CTH) is available at


About IntelGenx Corp.

IntelGenx Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx has developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The company’s research and development pipeline includes products for the treatment of osteoarthritis, pain management, smoking cessation, and seasonal affective disorder. More information about IntelGenx is available at


Contact Information

Cannasat Therapeutics Inc.
Andrew Williams
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]


Forward Looking Statement

Certain statements in this release may constitute forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors, which may cause actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.


The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on